{"links":{"feed":"https://www.erudio.com/reports/interpath-014-nct07513376/feed.json","html":"https://www.erudio.com/reports/interpath-014-nct07513376","json":"https://www.erudio.com/reports/interpath-014-nct07513376.json","markdown":"https://www.erudio.com/reports/interpath-014-nct07513376.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"interpath-014-nct07513376"}},"request":"https://www.erudio.com/contact?report=interpath-014-nct07513376"},"offer":{"cited_clinicians":1,"cited_commentary_sources":18,"verified_hcp_statements":79,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":2},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=interpath-014-nct07513376","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=interpath-014-nct07513376","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/interpath-014-nct07513376","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 79 verified statements · 1 from 1 confirmed clinician","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T13:59:12.931715Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":2},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":12,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":10,"coverage":"discussed","id":"A1","source_count":4,"title":"Postoperative manufacturing, tissue and timing"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":3,"title":"Administration route and workflow"},{"claim_count":15,"coverage":"discussed","id":"A3","source_count":3,"title":"Research access, eligibility review and patient support"},{"claim_count":28,"coverage":"discussed","id":"A4","source_count":6,"title":"Cross-cancer expectations, mutation burden and vaccine-only uncertainty"},{"claim_count":8,"coverage":"discussed","id":"A5","source_count":6,"title":"Commercial expectations and economic uncertainty"},{"claim_count":2,"coverage":"discussed","id":"A6","source_count":2,"title":"Comparison with neoadjuvant checkpoint blockade"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":20,"cited_clinicians":1,"cited_clinicians_by_role":{"physician":1},"cited_physicians":1,"cited_sources":18,"claims_by_expression_type":{"comparison":5,"experience":2,"interpretation":22,"opinion":12,"question":2,"restatement":13,"uncertainty":7,"unspecified":16},"claims_by_kind":{"interpretation":13,"limitation":3,"source_observation":63},"clinician_statements":1,"evidence_units":27,"findings":10,"organisational_accounts":3,"people_cited":3,"people_identity_verified":2,"people_total":3,"screened_sources":22,"verified_claims":79},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":2,"views":3},"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":6,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Vaccine monotherapy: what speakers say","evidence_line":"7 statements from 1 speaker in 5 sources"},{"cited_clinicians":0,"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":4,"views":2},"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":0,"passages":7,"sources":7,"sources_by_kind":{"commentary":7}},"title":"INTerpath-014: some speakers see design information, not a lung efficacy readout","title_holders":{"cited_claim_ids":["claim-ebef01c85fbc8f7b9139","claim-52d8b188ae1ef99682ca","claim-4864b5e2f9ebb1536550"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"8 statements in 7 sources","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":1,"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":0,"views":2},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"High-risk stage I NSCLC: why speakers welcome testing treatment earlier","title_holders":{"cited_claim_ids":["claim-ada926874957b5be57fc","claim-65a11d89dd001e2eb412","claim-18df763938885a41035f"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"4 statements from 2 speakers in 2 sources","holder_line":"2 of the 2 named speakers in this finding hold this view"},{"cited_clinicians":0,"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":6,"views":3},"limitations":5,"links":{"context":0,"support":13},"ma_question":true,"named_voices":0,"passages":4,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Intismeran supply: speakers see limits, but one accepts the launch case","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-b1948a42e4e37a187184"],"clause":"one accepts the launch case","holders":0},"cited_claim_ids":["claim-8b4de5f4878fcb7f699f","claim-4df7d82e420193dc600a","claim-281933d0276f908dc981","claim-d8ffb803d4fbb6ee3a71","claim-ec851b560a6c7f886c85"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"9 statements in 4 sources, 1 of them a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":0,"id":"F5","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":2},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":0,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"SC use: a speaker cites IV time, and one sees franchise value if it works","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-f4fcd0d9f2a06af999c0"],"clause":"one sees franchise value if it works","holders":0},"cited_claim_ids":["claim-36bd40a9f446123cbbed"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"4 statements in 3 sources","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":0,"id":"F6","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":8,"views":7},"limitations":4,"links":{"context":1,"support":15},"ma_question":true,"named_voices":0,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"Trial access: what speakers say","evidence_line":"15 statements in 2 sources, all podcasts or videos"},{"cited_clinicians":0,"id":"F9","structure":{"claims":8,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":2,"views":2},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":0,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Colorectal vaccine data: speakers limit extrapolation, but stress PD-1 context","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-5ed550598b17a5045f72","claim-f1e61472ecb165f1032b","claim-f890387d6e4503f555c0"],"clause":"stress PD-1 context","holders":0},"cited_claim_ids":["claim-f1e61472ecb165f1032b","claim-b9bd2962ff4fc6c64373","claim-d94a82a12efb9e249de4","claim-f890387d6e4503f555c0"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"8 statements in 2 sources","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":0,"id":"F10","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":6},"limitations":3,"links":{"context":0,"support":15},"ma_question":false,"named_voices":1,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Commercial expectations: what speakers say","evidence_line":"10 statements from 1 speaker in 6 sources"},{"cited_clinicians":0,"id":"F7","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":0},"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":0,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Lung vaccines: why a speaker expects no edge over neoadjuvant checkpoint inhibition","title_holders":{"cited_claim_ids":["claim-9245153ed516a6d5217a"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"2 statements in 2 sources","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":0,"id":"F8","population":"beyond","structure":{"claims":20,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":6,"views":10},"limitations":3,"links":{"context":1,"support":20},"ma_question":true,"named_voices":0,"passages":7,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Melanoma: most speakers need lung data; most see conditional trial support","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-3151d477ceafd736bfe0","claim-53d9b1231dea227ae2e4","claim-7fd6070f9041a70c5cdc","claim-ced037ad095f38ac1a11","claim-a2dc78e5ee8f109f0559","claim-eef813ca6f3d4137c154","claim-006604b7f570e7312c33"],"clause":"most see conditional trial support","holders":0},"cited_claim_ids":["claim-a9e40ebe760d10905747","claim-ced037ad095f38ac1a11","claim-43460bd279d65e708acf","claim-a2dc78e5ee8f109f0559","claim-eef813ca6f3d4137c154"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"20 statements in 5 sources, 1 of them a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"X accounts contest certainty about checkpoint dependence"},{"id":"section-2","level":2,"title":"X accounts distinguish the ESMO design presentation from a lung-cancer readout"},{"id":"section-3","level":2,"title":"Two authors described as trial-involved welcome earlier investigation"},{"id":"section-4","level":2,"title":"An X account and a video discussion identify practical timing constraints"},{"id":"section-5","level":2,"title":"One X account favors a workflow explanation for subcutaneous treatment; another distinguishes a commercial inference"},{"id":"section-6","level":2,"title":"Video discussions direct access questions back to individual physician review"},{"id":"section-7","level":2,"title":"One X account interprets colorectal monotherapy experience through product and disease-setting differences"},{"id":"section-8","level":2,"title":"X accounts question commercial expectations while clinical and manufacturing answers remain uncertain"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"One X account questions whether vaccine-based therapy can outperform neoadjuvant checkpoint blockade"},{"id":"section-11","level":3,"title":"Several accounts limit what melanoma evidence can establish for lung cancer"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T1","label":"Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":5},{"id":"F9","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":2},{"id":"F10","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":8},{"id":"F3","shared_claims":2},{"id":"F10","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T13:59:12.931715Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T14:10:45Z","record_hash":"c37aaa59f5ae128a1a6c21e01bf85ae4a81b80e15eca52bf947ec718c20e0169","release_hash":"9bd4cd18fd851b00956dcad585ec8613464af354451493d2a76c50bee115fa79","report_id":"erudio-nct07513376","run_id":"b87f131c-4015-4e19-ac20-7ccae95f2b8d","schema_version":"5.0","slug":"interpath-014-nct07513376","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For INTerpath-014, a speaker regards benefit without pembrolizumab as unresolved because earlier melanoma signals arose with combination treatment, while another asserts intismeran requires pembrolizumab. Their clinical roles are not established, and the commentary offers no assessment of the trial’s benefit or tolerability.","examples":[],"meta_description":"22 sources screened · 79 verified statements (1 from clinicians verified by NPI or staff page) from 18 sources · 10 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T14:10:45Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-22T14:10:45Z","kind":"routine","summary":"The trial's name is spelled as its investigators write it, “INTerpath-014” (NCT07513376), outside quotations (was “INTERpath”, “INTERpath-014”)."},{"affected_ids":[],"date":"2026-11-22T15:13:51Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":22},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, capacity and access barriers in resectable lung cancer; a view on actual vaccine receipt and time to dosing when evaluating adjuvant vaccination.","17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 43 sources about other trials or topics are not included.","The sources reviewed for this edition are selected public discussions, not a representative sample of HCP views. Repeated posts by one account do not establish independent agreement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The exact trial protocol and a results publication for NCT07513376 were not found in the reviewed materials. The cited congress statements describe trial design rather than efficacy results and do not provide an INTerpath-014 safety assessment.","Exact product labels were not available for independent assessment of approval-scope statements. Access, pricing and regulatory expectations remain attributed, time-specific accounts.","Melanoma subgroup findings and comparisons with another vaccine in colorectal cancer are exploratory or cross-trial context, not evidence of benefit or harm in INTerpath-014.","Source accounts differ on study-start timing. The August 2034 primary-completion date is an estimate, and an account's eight-year readout interpretation is not a guaranteed timetable.","The neoadjuvant comparison does not include a full account of the connected perioperative-immunotherapy evidence or concerns about testing, capacity and access; it should not be read as a comprehensive comparison."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":18},"count":18,"evidence_window":{"end":"2026-10-26","start":"2026-04-27"},"retrieval_snapshot":"2026-11-22T13:16:22.458977Z","timeline":[{"count":1,"week":"2026-W18"},{"count":3,"week":"2026-W34"},{"count":1,"week":"2026-W37"},{"count":2,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":3,"week":"2026-W41"},{"count":3,"week":"2026-W42"},{"count":3,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07513376:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07513376:context","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7454535496971747328","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090041549514027238:813df8c9-b6a5-49ce-922b-b72ec593df88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090190664713539647:85430323-d4a9-4462-bae0-001ce4cd1014","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090335942787911870:4bc67f8f-d8ba-42cc-835f-0551396fd933","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097300892126961734:3771ffae-7b23-4949-b54f-d769f6b751a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098056908447912218:e1098711-3668-479d-94a0-cc2af60dfd63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100229574974222465:8f1efb1a-07e2-4f45-98c1-9d9f60297e6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100230647755559013:95f56c5b-cfa5-4174-94c5-8dc539be3cae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102042969234706870:6faf4330-0a37-487f-8d3b-b67026ae3dc7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102055118753735144:ad314197-f8e9-4f8d-9eb2-fb0e883e5b4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102493766536077598:3f8ea7c4-8fb2-4796-8340-1935eb1d68e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107589694368424228:f0e0e82b-f811-4739-83f5-aa27dbe13ff3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107684719156670556:1906bd03-3ecc-4d6e-ba1c-f826f58a15e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107699185281867943:7f3d047c-b7ac-4c80-a59f-4b94bce843a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109696377139900518:b0d806a2-a802-42b9-8d63-a0c39ea461c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110782870541209762:71203cff-16d9-48aa-9ec2-18b0447e9507","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112047038384984081:b045eab7-88c2-4bb5-8c74-c9ddbb787834","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113005604826456071:fa7af84c-1cf8-498d-b145-263a75692bd4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114102515591418144:e1a277c1-19c6-41a1-b979-ccc927c39f59","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114585956149862621:ebf8a6a3-0257-4864-ad69-cfbb91d6abba","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1b4wvQQC4oc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:kAISDgTMXvQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":22},"count":22,"evidence_window":{"end":"2026-10-26","start":"2026-04-27"},"retrieval_snapshot":"2026-11-22T13:16:22.458977Z","timeline":[{"count":1,"week":"2026-W18"},{"count":4,"week":"2026-W34"},{"count":2,"week":"2026-W37"},{"count":2,"week":"2026-W38"},{"count":3,"week":"2026-W39"},{"count":3,"week":"2026-W41"},{"count":3,"week":"2026-W42"},{"count":3,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":3,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":56,"x_video":0,"youtube":20}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"intismeran autogene","slug":"intismeran-autogene"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"INTerpath-014","aliases":["INTerpath-014","A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)","A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)"],"brief_title":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)","collaborators":["ModernaTX, Inc."],"conditions":["Non-small Cell Lung Cancer"],"display_condition":"resected high-risk stage I non-small cell lung cancer","display_interventions":[["intismeran autogene","MK-3475A"],["intismeran autogene"]],"enrollment":{"count":876,"type":"ESTIMATED"},"interventions":[{"name":"Intismeran","synonyms":["V940","mRNA-4157"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab coformulated with berahyaluronidase alfa","synonyms":["MK-3475A"],"type":"BIOLOGICAL"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT07513376","official_title":"A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2034-08-22","type":"ESTIMATED"},"primary_endpoints":[{"description":"DFS is defined as the time from randomization to any recurrence (local, locoregional, regional, or distant) by BICR, or death due to any cause, whichever occurs first.","measure":"Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C","timeFrame":"Up to approximately 98 months"}],"registered_date":{"date":"2026-04-07","type":"ACTUAL"},"registry_last_updated":"2026-11-16","registry_url":"https://clinicaltrials.gov/study/NCT07513376","short_name":"INTerpath-014","short_name_basis":"registry_acronym","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2026-05-04","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"V940-014","type":"sponsor_study_id"},{"domain":"UTN","id":"U1111-1323-9950","type":"registry"},{"domain":"EU CT","id":"2025-522643-18-00","type":"registry"},{"domain":"Japan Registry of Clinical Trials (jRCT)","id":"jRCT2021260028","type":"registry"}],"study_type":"INTERVENTIONAL"}}}